Compare · AZN vs INSM
AZN vs INSM
Side-by-side comparison of AstraZeneca PLC (AZN) and Insmed Incorporated (INSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and INSM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 11.2x INSM ($23.48B).
- Over the past year, AZN is down 10.3% and INSM is up 5.6% - INSM leads by 15.9 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 11 for INSM).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Insmed Incorporated
- Price
- $168.85-0.24%
- $108.28+0.73%
- Market cap
- $261.92B
- $23.48B
- 1M return
- -5.56%
- +13.38%
- 1Y return
- -10.32%
- +5.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 15
- 11
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest INSM
- Insmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
- Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,256,084 worth of shares (10,699 units at $117.40) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Flammer Martina M.D. exercised 12,302 shares at a strike of $25.80 and sold $1,352,932 worth of shares (12,302 units at $109.98) as part of a pre-agreed trading plan (SEC Form 4)
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- FDA Approval for ARIKAYCE KIT issued to INSMED INC
- Chair and CEO Lewis William sold $2,210,763 worth of shares (21,398 units at $103.32) as part of a pre-agreed trading plan and exercised 21,398 shares at a strike of $24.94 (SEC Form 4)
- SVP, GM, Global Respiratory Butera Samuele was granted 7,342 shares (SEC Form 4)
- SEC Form 3 filed by new insider Butera Samuele
- Chief Legal Officer Smith Michael Alexander sold $173,051 worth of shares (1,806 units at $95.82) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 37,648 units (SEC Form 4)